Peptide News Digest

MultiValent Biotherapies $27M Series A for Prostate Cancer PDC, Tirzepatide PNAS Nexus Real-World Beats Semaglutide, JAMA Viewpoint on Online Peptide Regulation Gap, Business Group on Health: 10% of Employers Plan to Drop GLP-1 in 2027

MVB-101 PSMA × FRα prostate PDC launches with $27M, PNAS Nexus tirzepatide vs semaglutide real-world, JAMA viewpoint on online peptides, employer GLP-1 drop.

5 stories · Covering industry, research, clinical-trials

Editor's Note

ENDO 2026's final day in Chicago coincided with three substantive non-conference signals reshaping how the peptide field gets paid for, sold, and policed. MultiValent Biotherapies emerged from stealth with a $27 million Series A and rights to MVB-101, a PSMA × folate-receptor-alpha dual-target peptide-drug conjugate licensed from Coherent Biopharma, with a Phase 1b/2a in prostate cancer slated for Q3 2026. Venkatakrishnan and colleagues published in PNAS Nexus a real-world comparison of tirzepatide and semaglutide in obesity care, showing 14.7% vs 10.8% mean weight loss at one year, nearly twice the rate of high responders (more than 15% weight loss) on tirzepatide, fewer GI and fatigue adverse events, and a demographic gradient in which female and white patients responded better on either drug than male, black, or Hispanic patients. A JAMA Viewpoint from researchers at the University of Queensland, the University of Toronto, and UCSF flagged the regulatory gap underneath the social-media-driven injectable-peptide surge (130,000-plus Instagram posts, more than 230 million TikTok views). And the Business Group on Health June 2026 survey of 105 large employers reported that roughly one in ten companies currently covering GLP-1s for obesity expect to drop that coverage in 2027 as overall costs climb despite per-unit price cuts.

Industry

MultiValent Biotherapies Launches With $27M Series A to Develop MVB-101, a PSMA × Folate-Receptor-Alpha Dual-Target Peptide Drug Conjugate for Prostate Cancer

MultiValent Biotherapies announced June 16 a first closing of $27.425 million in Series A financing to advance MVB-101, a PSMA × folate-receptor-alpha (FRα) dual-target peptide-drug conjugate licensed from China-based Coherent Biopharma (originally CBP-1018). MVB-101 binds two validated prostate-cancer targets simultaneously; existing PDCs and radioligand therapies (Pluvicto, Lutathera) hit one target each. MultiValent holds exclusive global rights outside greater China. A Phase 1b/2a clinical trial in a subgroup of prostate cancer patients is planned to start in Q3 2026. The launch adds another oncology PDC to a field still dominated by Pluvicto (lutetium-177 PSMA-617), Lutathera, and Pfizer's AVA6000 FAP-Dox.

#multivalent-biotherapies #mvb-101 #psma #folate-receptor-alpha #peptide-drug-conjugate #prostate-cancer #coherent-biopharma #series-a
Research

PNAS Nexus Real-World Comparison: Tirzepatide Drives 14.7% vs Semaglutide 10.8% Mean Weight Loss, Nearly Twice the High-Responder Rate, Fewer GI and Fatigue Events

A real-world comparison of tirzepatide and semaglutide for obesity by Venkatakrishnan and colleagues, published in PNAS Nexus on June 16, reported mean body-weight reductions of 14.7% on tirzepatide versus 10.8% on semaglutide at one year. The tirzepatide arm produced close to twice the proportion of 'high responders' (more than 15% body-weight loss) and lower rates of GI events, headache, and fatigue. Female and white patients responded more strongly on either drug than male, black, or Hispanic patients, who were more frequently in the under-5% weight-loss tier. The findings track with SURMOUNT-5's head-to-head trial result and the April 13 OMA Truveta poster but add a new demographic-disparity dimension that should inform real-world treatment selection.

#tirzepatide #semaglutide #real-world-evidence #pnas-nexus #obesity #demographic-disparities #high-responders
Research

JAMA Viewpoint: The Online Injectable-Peptide Surge Has Outrun Regulation, Researchers Warn

A JAMA Viewpoint published June 15 by researchers from the University of Queensland, the University of Toronto, and the University of California, San Francisco flagged a fast-growing but poorly characterized trend: social-media-promoted injectable peptides for muscle growth, recovery, anti-aging, and cognition. The piece notes 130,000-plus Instagram posts and over 230 million TikTok views as of May 2026, plus a 6x rise in worldwide Google searches for 'peptides' between 2024 (1.3M/month) and 2026 (~8M/month). Substances cited include BPC-157, TB-500, and CJC-1295. The authors call for accelerated safety research and clearer regulation; the piece lands six weeks before the July 23-24 PCAC meeting that will weigh seven of those same substances for 503A compounding status.

#jama #injectable-peptides #bpc-157 #tb-500 #cjc-1295 #regulation #social-media #pcac
Industry

Business Group on Health Survey: 67% of Large Employers Cover GLP-1s for Obesity, But Roughly 1 in 10 Plan to Drop Coverage in 2027

The Business Group on Health's June 2026 survey of 105 large US employers found 67% currently cover GLP-1 drugs for weight management, but about 10% of those covering plan to drop coverage in 2027 as total spending continues to climb even as per-unit GLP-1 prices have fallen. The Foundayo and Wegovy pill launches drew in patients who had not previously tried GLP-1 therapy, increasing aggregate utilization. Employers that continue covering are layering on management strategies: required participation in a weight-management program, biometric eligibility verification, and restricted prescribing to specific providers. The 2027 employer-coverage cliff is the next financial pressure point for Lilly, Novo, and the pharmacy benefit managers that have built obesity formularies around employer-sponsored plans.

#business-group-on-health #glp-1 #employer-coverage #pbm #2027-coverage-cliff #obesity-coverage
Clinical Trials

Medscape (June 16): Tirzepatide Reverses Postbariatric Weight Regain in University of Catania Study

A Medscape clinical study report June 16 from Federica Vinciguerra and colleagues at the University of Catania documented that tirzepatide reversed post-bariatric-surgery weight regain in patients several years out from sleeve gastrectomy or gastric bypass. Post-surgical weight regain affects roughly 50% of bariatric patients within 2-5 years; until recently, the field had no pharmacologic option that meaningfully reversed it. The Catania data add to the case that GLP-1 incretin therapy is a credible second-line option for the post-surgical regain population, distinct from bariatric revision surgery and the 503A/503B compounded-GLP-1 channel.

#tirzepatide #post-bariatric #weight-regain #sleeve-gastrectomy #gastric-bypass #secondary-treatment